We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Primary Care

Expert Opinion / My Approach · March 01, 2016

MY APPROACH to Treating Menopause

Written by
Naiomi Jamal MD
Tricia C. Elliott MD, FAAFP

 

Additional Info

  1. The role of isoflavones in menopausal health: consensus opinion of The North American Menopause Society. Menopause. 2000;7(4):215-229.
  2. Nonhormonal management of menopause-associated vasomotor symptoms: 2015 position statement of The North American Menopause Society. Menopause. 2015;22(11):1155-1172.
  3. Dew TP, Williamson G. Controlled flax interventions for the improvement of menopausal symptoms and postmenopausal bone health: a systematic review. Menopause. 2013;20(11):1207-1215.
  4. Wu WH, Liu LY, Chung CJ, et al. Estrogenic effect of yam ingestion in healthy postmenopausal women. J Am Coll Nutr. 2005;24(4):235-243.
  5. Komesaroff PA, Black CV, Cable V, Sudhir K. Effects of wild yam extract on menopausal symptoms, lipids and sex hormones in healthy menopausal women. Climacteric. 2001;4(2):144-150.
  6. Leach MJ, Moore V. Black cohosh (Cimicifuga spp.) for menopausal symptoms. Cochrane Database Syst Rev. 2012;9:CD007244.
  7. Uebelhack R, Blohmer JU, Graubaum HJ, et al. Black cohosh and St. John's wort for climacteric complaints: a randomized trial. Obstet Gynecol. 2006;107(2 Pt 1):247-255.
  8. Hirata JD, Swiersz LM, Zell B, et al. Does dong quai have estrogenic effects in postmenopausal women? A double-blind, placebo-controlled trial. Fertil Steril. 1997;68(6):981-986.
  9. Cagnacci A, Arangino S, Renzi A, et al. Kava-Kava administration reduces anxiety in perimenopausal women. Maturitas. 2003;44(2):103-109.
  10. Tice JA, Ettinger B, Ensrud K, et al. Phytoestrogen supplements for the treatment of hot flashes: the Isoflavone Clover Extract (ICE) Study: a randomized controlled trial. JAMA. 2003;290(2):207-214.
  11. Mann E, Smith M, Hellier J, Hunter MS. A randomised controlled trial of a cognitive behavioural intervention for women who have menopausal symptoms following breast cancer treatment (MENOS 1): trial protocol. BMC Cancer. 2011;11:44.
  12. Ayers B, Smith M, Hellier J, et al. Effectiveness of group and self-help cognitive behavior therapy in reducing problematic menopausal hot flushes and night sweats (MENOS 2): a randomized controlled trial. Menopause. 2012;19(7):749-759.
  13. Elkins G, Marcus J, Stearns V, et al. Randomized trial of a hypnosis intervention for treatment of hot flashes among breast cancer survivors. J Clin Oncol. 2008;26(31):5022-5026.
  14. Elkins GR, Fisher WI, Johnson AK, et al. Clinical hypnosis in the treatment of postmenopausal hot flashes: a randomized controlled trial. Menopause. 2013;20(3):291-298.
  15. Saensak S, Vutyavanich T, Somboonporn W, Srisurapanont M. Relaxation for perimenopausal and postmenopausal symptoms. Cochrane Database Syst Rev. 2014;7:CD008582.
  16. Sood R, Sood A, Wolf SL, et al. Paced breathing compared with usual breathing for hot flashes. Menopause. 2013;20(2):179-184.
  17. Carmody JF, Crawford S, Salmoirago-Blotcher E, et al. Mindfulness training for coping with hot flashes: results of a randomized trial. Menopause. 2011;18(6):611-620.
  18. Thurston RC, Ewing LJ, Low CA, et al. Behavioral weight loss for the management of menopausal hot flashes: a pilot study. Menopause. 2015;22(1):59-65.
  19. Huang AJ, Subak LL, Wing R, et al. An intensive behavioral weight loss intervention and hot flushes in women. Arch Intern Med. 2010;170(13):1161-1167.
  20. Kroenke CH, Caan BJ, Stefanick ML, et al. Effects of a dietary intervention and weight change on VMS in the Women’s Health Initiative. Menopause. 2012;19(9):980-988.
  21. Guthrie JR, Dennerstein L, Hopper JL, Burger HG. Hot flushes, menstrual status, and hormone levels in a population-based sample of midlife women. Obstet Gynecol. 1996;88(3):437-442.
  22. Daley A, Stokes-Lampard H, Macarthur C. Exercise for vasomotor menopausal symptoms. Cochrane Database Syst Rev. 2011;5:CD006108.
  23. Daley A, Stokes-Lampard H, Thomas A, MacArthur C. Exercise for vasomotor menopausal symptoms. Cochrane Database Syst Rev 2014;11:CD006108.
  24. FDA. Background document for meeting of advisory committee for reproductive health: NDA 204-516 Paroxetine mesylate capsules 7.5 mg. March 4, 2013. Available at: Drugshttp://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ReproductiveHealthDrugsAdvisoryCommittee/UCM341590.pdf. Accessed on February 22, 2016.
  25. Brown JN, Wright JR. Use of gabapentin in patients experiencing hot flashes. Pharmacotherapy. 2009;29(1):74-78.
  26. Nelson HD, Vesco KK, Haney E, et al. Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis. JAMA. 2006;295(17):2057-2071.
  27. American College of Obstetricians and Gynecologists (ACOG). Practice bulletin no. 141: management of menopausal symptoms. Obstet Gynecol. 2014;123:202–216.
  28. USPSTF. Menopausal hormone therapy: preventive medication. October 2012. Available at: http://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/menopausal-hormone-therapy-preventive-medication?ds=1&s=menopause. Accessed on February 22, 2016.
  29. Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society Menopause. Menopause. 2013;20(9):888-902.
  30. Suckling J, Lethaby A, Kennedy R. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev. 2006;4:CD001500.
  31. Portman DJ, Bachmann GA, Simon JA; Ospemifene Study Group. Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy. Menopause. 2013;20(6):623-630.
  32. Bachmann GA, Komi JO; Ospemifene Study Group. Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study. Menopause. 2010;17(3):480-486.

Disclosure statements are available on the authors' profiles:

Further Reading